BIOBRIEF
The 6 1 ruling forecloses a legal theory that would have let HIV patients sue drugmakers for delaying safer successors, but other claims against Gilead survive.
California's top court on Monday rejected a legal theory that would have let more than 24,000 HIV patients sue Gilead Sciences for marketing an older, riskier drug while a safer successor sat in development. The 6-1 ruling overturns a 2024 California Court of Appeal decision and forecloses the so-called 'duty to innovate,' a theory that would have let patients recover for delays in bringing a less-toxic successor to market, not just for harms from the drug they took.
The plaintiffs alleged that Gilead's tenofovir disoproxil fumarate (TDF) caused kidney injury and bone loss, and accused the company of "cynically managing" its pipeline to extend the older drug's revenue while the safer tenofovir alafenamide (TAF) sat in development. The Supreme Court's majority refused to convert ordinary R&D decisions into a tort duty.
The lone dissent has not yet been characterized in public summaries. The case, Gilead Tenofovir Cases, S283862, was argued May 6, 2026.
The decision is narrow. Patients may still pursue failure-to-warn and design-defect claims, and parallel federal litigation continues. Industry amici, including PhRMA, BIO, and the U.S. Chamber, had warned the duty would chill R&D. Plaintiffs' attorneys argue the ruling immunizes routine pipeline choices. Gilead's litigation page presents the company's framing.